Investor Overview

Stock Information
Loading data...

Shares outstanding

100,328,686 (as of 08/08/2024)

Press Releases
Nov 14, 2024

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — —...

Nov 6, 2024

Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to...

Oct 28, 2024

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today...

Sep 20, 2024

Endometriosis Affects Approximately 190 Million Women Worldwide Non-invasive MET™ Diagnostic Test for Endometriosis Leverages Novel Biomarker: A Specific Deletion in Mitochondrial DNA...

Sep 9, 2024

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB:...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel.

  • The U.S. contraceptive market was estimated at $8.3 billion as of 2022.
  • Every 1% market share of the 43.3 million women in Evofem's addressable market represents more than $450 million in net product sales for the Company.
  • 2023 marked the third consecutive year of Phexxi net sales growth.  

In July 2024, Evofem acquired global rights to its second women’s health product, SOLOSEC® (secnidazole) 2g oral granules.  This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.  Evofem plans to re-launch SOLOSEC in the U.S. in the second half of 2024, leveraging its commercial infrastructure and strong physician relationships.

Evofem intends to expand the global reach of its products and further increase its commercial potential through ex-U.S. licenses. Phexxi is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

On December 11, 2023, Evofem and Aditxt, Inc. (Nasdaq: ADTX) entered into an Agreement and Plan of Merger by and between the companies (the "Merger Agreement"). The parties amended and restated the Merger Agreement, as amended, in its entirely on July 12, 2024 (the "A&R Merger Agreement"); there have been several subsequent amendments. 

Evofem believes the proposed Transaction represents a compelling opportunity to accelerate its growth trajectory, as a subsidiary of Aditxt, into a multi-product women's health franchise. The companies are working toward close in late 2024.

The Company's common stock currently trades on the OTCQB Venture Market under the ticker symbol "EVFM".

Featured Event
Monday, October 28, 2024
11:30 am EDT

Saundra Pelletier, CEO of Evofem Biosciences, joined Aditxt CEO Amro Albanna and MD and media personality Dr. Drew Pinsky for a Virtual Fireside Chat on October 28, 2024.

View All

Latest Financial Results

Q2 ended June 30, 2024

Earnings Release
10-Q Filing
XBRL